Summary The synthetic polypeptide, poly-L-aspartic acid (PAA, mol. wt = 20,000) has been used as a macromolecular carrier for doxorubicin. The drug may be released in vivo through hydrolysis of the ester linkage formed between the carboxyl groups of the polymer and the drug side chain. PAA has been found to be a suitable carrier since it is a soluble, biodegradable, multivalent and nontoxic polymer. The toxicity and the therapeutic efficacy of free and polymer-linked doxorubicin have been evaluated in normal and tumourbearing mice, using a variety of experimental tumour systems. In studies on single and multiple drug administration, the results indicated that the polymeric derivative of doxorubicin had approximately 3-fold lower toxicity than did free drug. In addition, the severity of specific toxic effects, including cardio-and vesicant toxicity, were appreciably reduced following conjugation to PAA. The doxorubicin-PAA conjugate gave similar or rather greater therapeutic effects than free drug at less toxic doses. This effect, more evident in the highly sensitive tumours, suggests an improvement of the therapeutic index of the polymer-linked drug.
In an attempt to improve tumour drug uptake and, therefore, the selectivity of antitumour agents, many carrier systems have been tested. Means of drug delivery include target-specific biological carriers (Ghose et al., 1983) as well as other nonspecific microparticulate, macromolecular and synthetic carriers (Gregoriadis, 1981; Gros et al., 1981) . Macromolecular drug carrier systems have been extensively developed in an attempt to modify the pharmacokinetic behaviour of antitumour drugs (Kaye, 1981) .
Although preferential delivery of the drug to tumour cells remains to be documented, linkage of cytotoxic agents to suitable macromolecules has been found to improve therapeutic efficacy (Arnon & Hurwitz, 1983) . In some cases, the therapeutic advantage of the macromolecular derivative is related to reduction of systemic drug toxicity, thus allowing the administration of higher doses (LeviSchaffer et al., 1982) .
Recently, we have reported that daunorubicin covalently linked to poly-L-aspartic acid (PAA) reduce the toxicity of the anthracycline, whereas it maintained or improved the antitumour efficacy (Zunino et al., 1982 (Zunino et al., , 1984 . Doxorubicin may be released in vivo through hydrolysis of the ester linkage formed between the carboxyl group of the polymer and drug side chain. These results have generated considerable interest, since the polymeric drug form might be of potential clinical relevance.
Thus, the present studies were initiated to further document the preclinical efficacy of doxorubicin conjugated with PAA. Polymer-bound doxorubicin was compared to free drug with respect to some toxic effects. In addition, this paper describes detailed in vivo evaluation of free and PAA-bound doxorubicin against experimental tumour systems with particular reference to solid tumours.
Materials and methods

Drugs
Daunorubicin, doxorubicin and 14-bromo-daunorubicin were supplied by Farmitalia Carlo Erba (Milan, Italy) as hydrochlorides. Drug solutions were freshly prepared immediately before use. PAA (mol. wt 20,000) was obtained from Sigma Chemical Co. (St Louis, Mo., USA). Doxorubicin-PAA conjugate (poly-L-aspartic acid doxorubicinyl ester; previously referred to as daunorubicin-PAA conjugate since a daunorubicin derivative was used in the conjugation procedure) was prepared essentially according to the previously described procedure (Zunino et al., 1982 (Zunino et al., , 1984 (Bertazzoli et al., 1979) . Myocardial lesions were graded according to: (severity degree) x (extension degree). The histological examinations were blind.
The vesicant activity was assessed in SpragueDawley rats weighing about 250 mg. Rats were injected i.d. in both flanks with 1 ml of a solution containing different drug concentrations in distilled water. The healing scar was measured on day 12 on its largest dimension and was scored as follows: I + = _Smm; 2+ =6-lOmm; 3+ = >lOmm. Scores were added and expressed as a response fraction (RF) of the possible total cumulation score of 3 + for each rat (Jenkins & Corden, 1983) .
Tumours
The macrophage tumour J774 was serially maintained in ascitic form in female BALB/c mice. For chemotherapy experiments, 106 cell/mouse were injected i.p. in female BALB/c or CDF1 (BALB/c x DBA/2) mice (Tarnowski et al., 1979) .
Lewis lung carcinoma was serially maintained according to Geran et al. (1972) . The experiments were carried out in BDF1 (C57BL x DBA/2) mice, inoculated i.m. with 5 x 105 cells/mouse. M5076/73A (M5), a murine reticulum cell sarcoma, was transplanted i.m. in the right hind leg of female C57BL mice by injection of 5 x 105 cells/mouse, for serial passages and chemotherapy experiments (Talmadge et al., 1981) . In the ascitic form, 2 x 106 cells/mouse were implanted i.p. in female BDF1 mice.
Mammary adenocarcinoma, spontaneously arisen in a retired female C3H/He breeder, was transplanted in the left axillary region in female C3H/He mice. The chemotherapy experiment was carried out on second generation transplant in female C3H/He mice injected with 2 x 107 cells/mouse (Di Marco et al., 1972) .
Evaluation of antitumour activity Unless otherwise indicated, for antitumour activity experiments 10mice/group were used. The effect on survival is expressed as percentage ILS (increase in life span) calculated as follows: ILS= [(T/C) -1] x 100, where T/C is the median survival time (MST) of dying mice only in the treated group (T) divided by the MST of the untreated control group (C). Long-term (at least 90 days) survivors (LTS) were considered cured and were noted separately.
In the mice injected with solid growing tumours, tumour growth was assessed by weekly caliper measurement of the two tumour diameters and tumour weight was obtained according to Geran et al. (1972) . In experiments carried out against early tumour, the anti-tumour activity was established by the percentage of tumour growth inhibition of the treated mice as compared to the controls at the day indicated in each experiment.
In the experiments designed to evaluate antitumour activity against advanced tumours, tumour weight in individual mice was determined at the beginning of treatment, and tumour growth was then evaluated for individual mice as the percentage change in tumour weight 1 week after the last treatment. The data reported as relative tumour weight represent the average of individual tumour weight change for each group.
Student's t test was used for statistical comparisons.
Results
Toxicity in non-tumour-bearing mice Table I shows that linkage of the anthracycline to values were -15 and 37mgkg-' for doxorubicin and doxorubicin-PAA, respectively. Thus, the ratio between these equitoxic doses of doxorubicin-PAA and free doxorubicin was 2.5. The chronic lethal toxicity of the drug on the same strain caused by 4 weekly i.v. injections could be further reduced when given in the polymeric form; thus, the ratio between equitoxic doses of doxorubicin-PAA (18mgkg-1) and doxorubicin (6mg kg-1) was -3 in this experiment. Moreover, in C57BL mice, doxorubicin-PAA conjugate seemed definitely better tolerated than free doxorubicin using a multiple treatment schedule (q7d x 3, i.v.); in this strain, the ratio between equitoxic doses was more than 3 (doxorubicin-PAA 22.5mg kg' vs. doxorubicin < 6 mg kg -1).
Data from the cardiotoxic test in C3H female mice (Table II) showed that the linkage of the anthracycline to PAA also reduced this organspecific damage. The dose of doxorubicin-PAA must be increased 3-fold relative to free doxorubicin in order to produce a comparable effect in the heart. This parallels the effect on mortality.
The ulcerogenic potential of doxorubicin and its polymeric derivative was assessed in SpragueDawley rats (Table III) . The vesicant action of (Zunino et al., 1982 (Zunino et al., , 1984 and, as already observed for other antitumour drugs, optimal treatment was at the maximum tolerated doses, in antitumour activity experiments the dose levels were usually selected in the range of the highest non-toxic doses (.LD1O). The relative effectiveness of doxorubicin, in the survival time than did doxorubicin. However, the difference was not statistically significant. Table IV . When administered as a single dose i.p. one day after cell inoculation, daunorubicin slightly increased the survival time at the optimal dose of 3.3 mg kg-1. Doxorubicin and doxorubicin-PAA, at their respective optimal doses (6.6 and 32mgkg-1), markedly increased the survival time of the tumour-bearing mice, producing also longterm survivors. Although the activity was comparable for the two drugs, doxorubicin-PAA gave more reproducible effects.
After a single i.p. treatment of M5 ascitic tumour (Table V) , doxorubicin-PAA gave a higher increase mice died from toxicity. Both the compounds had a similar effect on survival time. Table VIII compares the activity of doxorubicin and doxorubicin-PAA in the treatment of advanced mammary carcinoma (-.75 mg) implanted in C3H/He mice, with drug administration on the q7d x 4 (i.v.) schedule. At equitoxic doses (doxorubicin, 6mg kg-1 and doxorubicin-PAA, 18 mg kg 1), the conjugate produced a somewhat greater tumour inhibition (82%) than that produced by free doxorubicin (63%), although the difference was not statistically significant. Moreover, doxorubicin-PAA produced a similar inhibition (76%) at a non-toxic dose (15mgkg-1). Both drugs were ineffective in increasing survival time.
Discussion
The results presented in this study indicate that, in comparison to free drug, administration of doxorubicin covalently linked to the anionic polyamino acid, PAA, resulted in reduced toxicity, after single and after multiple administrations. Decreased systemic toxicity paralleled reduction in severity of specific toxic effects, including cardiotoxicity, probably related to decreased heart uptake of the drug (Mazzoni et al., in preparation). This observation is of particular interest, since potentially irreversible cardiac damage is the major doselimiting toxicity for doxorubicin (Lenaz & Page, 1976) . In particular, since in the same experiment (using healthy and tumour-bearing CH3 mice) we could compare cardiotoxic, lethal and anti-tumour effects, a therapeutic improvement following linkage of the anthracycline to the polymer could be directly shown (Tables II and VIII) . Indeed, although equitoxic doses of free doxorubicin (6mg kg-1) and doxorubicin-PAA (18mg kg-') caused comparable heart lesions and had similar effects on tumour growth, the doxorubicin-PAA conjugate retained anti-tumour activity at a lower In addition, the marked attenuation of dermal toxicity of the drug in the polymeric derivative might have obvious practical implications. Reduction of local toxicity is also consistent with the observation that high doses of the conjugate were well tolerated after i.p. administration (Zunino, 1982) . Again, this might have clinical relevance because of the therapeutic potential of doxorubicin in the intraperitoneal chemotherapy of abdominal neoplastic diseases (Myers & Collins, 1983) .
The anti-tumour activity, evaluated in a number of experimental models, indicated that doxorubicin linked to the polyamino acid provided therapeutic effects similar to those of free drug at less toxic doses. In fact, as summarised in Table IX , the data obtained in the treatment of three solid growing tumours do show a trend toward an improved therapeutic index of the drug following polymer linkage, although a quantitative assessment of this improvement is difficult to make due to the limited number of doses used in these experiments. An improvement in the therapeutic index resulting from conjugation was more evident in the MS model. Further studies aimed at other tumour models and different schedules would therefore be appropriate. Thus, although the covalent linkage of the drug to polymer also resulted in a reduction in drug potency, the therapeutic advantage, reflected by a greater margin of safety, was generally observed in a variety of experimental models (Zunino et al., 1982 (Zunino et al., , 1984 .
Moreover, the results indicated that the doxorubicin-PAA conjugate was also superior to free drug against MS tumour, a reticulum cell sarcoma (Talmadge et al., 1981) . It remains uncertain whether the increased therapeutic efficacy (Talmadge et al., 1982) , since apparently free and polymer-linked drug displayed comparable activity against the macrophage tumour J774. However, it should be noted that in two separate experiments (Table IV) , the efficacy of free doxorubicin in increasing survival time was markedly different, in contrast to the reproducible effect of the polymeric derivative. Thus, no definitive conclusions could be drawn from these experiments. Relevant to this point is the observation that in a variety of experimental models, reproducible results were generally obtained using different preparations of the conjugate. This also reflects the stability of the conjugate in aqueous solutions. Taken together with previous results showing an enhanced efficacy of the polymeric derivative as compared to free doxorubicin against leukaemia models (Zunino et al., 1984) , the data presented here suggest a therapeutic advantage of the drug linked to PAA in tumours of tissues of mesenchymal origin. Anyway, the attachment of doxorubicin to this macromolecular carrier did not cause loss or reduction of anti-tumour efficacy at optimal doses in any of the tumour models used. However, this means of drug delivery is not expected to overcome drug resistance, since free and polymer-linked doxorubicin produced a marginal response against colon carcinoma 26 (not shown), a tumour model, which, when growing subcutaneously, is relatively resistant to anthracycline therapy (Casazza et al., 1983) . This is in agreement with the absence of appreciable activity of the conjugate against a doxorubicin-resistant subline of P388 leukaemia (Zunino et al., 1982) .
Finally, it remains to be clarified whether the PAA conjugate has further therapeutic advantage over free drug, when administered in an optimal schedule. It should be noted that in all experiments only optimal schedules of free drug were employed.
In conclusion, among the favourable properties found for the doxorubicin-PAA conjugate in this and previous studies, the following are of particular interest: (i) reduced severity of some specific toxic effects; (ii) increased effectiveness against all of the leukaemia and sarcoma models tested; (iii) antitumour activity fully retained in other experimental tumour systems and (iv) improvement of the therapeutic index, more evident in the treatment of highly sensitive tumours (Gross leukaemia [Zunino et al., 1984] and M5 reticulum cell sarcoma [ Table VI] ).
Further studies on the preclinical toxicity of this polymeric derivative are needed to fully evaluate the therapeutic potential of this drug delivery system.
